[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100553871":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":38,"collaborators":19,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":19,"eligibilityCriteria":46,"healthyVolunteers":42,"sex":47,"minAge":19,"maxAge":48,"enrollmentInfo":49,"targetDuration":19,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":19,"overallStatus":60,"whyStopped":19,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"Beijing Friendship Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"iNK cells infusion patients","EXPERIMENTAL","Given iNK cell infusion after allo HSCT",[13],"Other: NCR300（Allogenic Ipsc-derived Natural Killer cells ）",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"NCR300（Allogenic Ipsc-derived Natural Killer cells ）","Patients will receive iNK cells i.V. infusion at 1.0x10\\^8\u002Fkg on days +14d, +21d, +28d, and +35d post-transplant.\n\nContinuation of the infusion after +35d post-transplant is at the discretion of the physician based on the patient's benefit.",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"zhao wang, MD","CONTACT","86010631383803","wangzhao@ccmu.edu.cn",[27],{"facility":28,"status":19,"city":29,"state":19,"zip":19,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":19},"Beijing Friendship Hospital, Capital Medical University","Beijing","China","CN",{"type":33,"coordinates":34},"Point",[35,36],116.39723,39.9075,{"lat":36,"lon":35},{"type":39,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100553871","a-study-on-efficacy-and-safety-of-ink-cells-for-caebv-ebv-hlh-after-allo-hsct-100553871",false,"NCT06491719","A Study on Efficacy and Safety of iNK Cells for CAEBV \u002FEBV-HLH After Allo-HSCT","A Study on Efficacy and Safety of iNK Cell Infusion in Patients With Chronic Active Epstein-Barr Virus Infection (CAEBV) and Epstein Barr Virus-induced Haemophagocytic Lymphohistiocytosis (EBV-HLH) After Allogeneic Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n1. Patients with CAEBV or EBV-HLH who are eligible for allogeneic hematopoietic stem cell transplantation meet one of the following criteria:\n\n   ①EBV-DNA (PBMC or plasma) was still more than 103 before transplantation；②Positive for Cerebrospinal fluid EBV-DNA；\n\n   ③Abnormal phenotypic lymphocytes could still be detected in bone marrow immunotyping；\n\n   ④Measurable EBV-related lesions on imaging；\n2. ≤65 years，ECOG :0-2；\n3. Cardiac EF≥40%, creatinine clearance ≥50%; aminotransferase（ALT\u002FAST）\\\u003C200U\u002FL。；\n4. In patients with HLH, HLH efficacy ≥Partial Response after prior treatment is required；\n5. Estimated survival time is longer than three months；\n6. Agree to sign the Informed Consent Form。\n\nExclusion Criteria:\n\n1. Patients with evidence of grade II or more serious heart disease according to the New York Heart Association (NYHA) score (including Grade II) ; Clear diagnosis of cirrhosis；\n2. Active infections other than EBV that have not yet been controlled；\n3. Positive for hepatitis B virus or hepatitis C virus；\n4. Active massive hemorrhage of internal organs (including gastrointestinal hemorrhage, alveolar hemorrhage, intracranial hemorrhage, etc.)；\n5. Also participation in other interventional clinical studies within 4 weeks","ALL","65 Years",{"count":50,"type":51},15,"ESTIMATED","INTERVENTIONAL",[54],"NA","To evaluate the efficacy and safety of iNK cells infusion in patients with chronic active Epstein-Barr virus infection (CAEBV) and EBV-associated hemophagocytic lymphohistiocytosis (EBV-HLH) after allogeneic hematopoietic stem cell transplantation (allo-HSCT)",[57,58,59],"CAEBV (Chronic Active Epstein-Barr Virus Infection) Syndrome","EBV","Hemophagocytic Lymphohistiocytoses","NOT_YET_RECRUITING","2024-07-09",{"date":63,"type":64},"2024-07-11","ACTUAL",{"date":66,"type":51},"2024-07-15",{"date":68,"type":51},"2026-07-15",{"name":5,"class":6},1]